Physiologic Effects of Stress Dose Corticosteroids in In-hospital Cardiac Arrest (CORTICA): A Randomized Clinical Trial

Aim: Postresuscitation hemodynamics are associated with hospital mortality/functional outcome. We sought to determine whether low-dose steroids started during and continued after cardiopulmonary resuscitation (CPR) affect postresuscitation hemodynamics and other physiological variables in vasopressor-requiring, in-hospital cardiac arrest.

Methods: We conducted a two-center, randomized, double-blind trial of patients with adrenaline (epinephrine)-requiring cardiac arrest. Patients were randomized to receive either methylprednisolone 40 mg (steroids group) or normal saline-placebo (control group) during the first CPR cycle post-enrollment. Postresuscitation shock was treated with hydrocortisone 240 mg daily for 7 days maximum and gradual taper (steroids group), or saline-placebo (control group). Primary outcomes were arterial pressure and central-venous oxygen saturation (ScvO) within 72 hours postROSC.

Results: Eighty nine of 98 controls and 80 of 86 steroids group patients with ROSC were treated as randomized. Primary outcome data were collected from 100 patients with ROSC (control, = 54; steroids, = 46). In intention-to-treat mixed-model analyses, there was no significant effect of group on arterial pressure, marginal mean (95% confidence interval) for mean arterial pressure, steroids vs. control: 74 (68-80) vs. 72 (66-79) mmHg] and ScvO [71 (68-75)% vs. 69 (65-73)%], cardiac index [2.8 (2.5-3.1) vs. 2.9 (2.5-3.2) L/min/m], and serum cytokine concentrations [e.g. interleukin-6, 89.1 (42.8-133.9) vs. 75.7 (52.1-152.3) pg/mL] determined within 72 hours post-ROSC ( = 0.12-0.86). There was no between-group difference in body temperature, echocardiographic variables, prefrontal blood flow index/cerebral autoregulation, organ failure-free days, and hazard for poor in-hospital/functional outcome, and adverse events ( = 0.08->0.99).

Conclusions: Our results do not support the use of low-dose corticosteroids in in-hospital cardiac arrest.ClinicalTrials.gov number: NCT02790788

Citing Articles

A Narrative Review of Drug Therapy in Adult and Pediatric Cardiac Arrest.

Jaeger D, Marquez A, Kosmopoulos M, Gutierrez A, Gaisendrees C, Orchard D Rev Cardiovasc Med. 2024; 24(6):163.

PMID: 39077526 PMC: 11264139. DOI: 10.31083/j.rcm2406163.

A critical reappraisal of vasopressin and steroids in in-hospital cardiac arrest.

Mentzelopoulos S, Chalkias A Crit Care. 2024; 28(1):191.

PMID: 38844995 PMC: 11155013. DOI: 10.1186/s13054-024-04962-8.

Effect of prehospital high-dose glucocorticoid on hemodynamics in patients resuscitated from out-of-hospital cardiac arrest: a sub-study of the STEROHCA trial.

Obling L, Beske R, Meyer M, Grand J, Wiberg S, Mohr T Crit Care. 2024; 28(1):28.

PMID: 38254130 PMC: 10801994. DOI: 10.1186/s13054-024-04808-3.

In-Hospital Cardiac Arrest.

Barros A, Enfield K Emerg Med Clin North Am. 2023; 41(3):455-464.

PMID: 37391244 PMC: 10549775. DOI: 10.1016/j.emc.2023.03.003.

General Critical Care, Temperature Control, and End-of-Life Decision Making in Patients Resuscitated from Cardiac Arrest.

Chalkias A, Adamos G, Mentzelopoulos S J Clin Med. 2023; 12(12).

PMID: 37373812 PMC: 10298925. DOI: 10.3390/jcm12124118.

References

Rajapandi T, Greene L, Eisenberg E . The molecular chaperones Hsp90 and Hsc70 are both necessary and sufficient to activate hormone binding by glucocorticoid receptor. J Biol Chem. 2000; 275(29):22597-604. DOI: 10.1074/jbc.M002035200. View

Ono M, Brady K, Easley R, Brown C, Kraut M, Gottesman R . Duration and magnitude of blood pressure below cerebral autoregulation threshold during cardiopulmonary bypass is associated with major morbidity and operative mortality. J Thorac Cardiovasc Surg. 2013; 147(1):483-9. PMC: 3865134. DOI: 10.1016/j.jtcvs.2013.07.069. View

Mentzelopoulos S, Mongardon N, Xanthos T, Zakynthinos S . Possible significance of hemodynamic and immunomodulatory effects of early stress-dose steroids in cardiac arrest. Crit Care. 2016; 20(1):211. PMC: 4952064. DOI: 10.1186/s13054-016-1384-4. View

Bro-Jeppesen J, Hassager C, Wanscher M, Ostergaard M, Nielsen N, Erlinge D . Targeted temperature management at 33°C versus 36°C and impact on systemic vascular resistance and myocardial function after out-of-hospital cardiac arrest: a sub-study of the Target Temperature Management Trial. Circ Cardiovasc Interv. 2014; 7(5):663-72. DOI: 10.1161/CIRCINTERVENTIONS.114.001556. View

Christ M, Meyer C, Sippel K, Wehling M . Rapid aldosterone signaling in vascular smooth muscle cells: involvement of phospholipase C, diacylglycerol and protein kinase C alpha. Biochem Biophys Res Commun. 1995; 213(1):123-9. DOI: 10.1006/bbrc.1995.2106. View

JASTREMSKI M, Sutton-Tyrrell K, Vaagenes P, Abramson N, Heiselman D, Safar P . Glucocorticoid treatment does not improve neurological recovery following cardiac arrest. Brain Resuscitation Clinical Trial I Study Group. JAMA. 1989; 262(24):3427-30. View

Vincent J, Moreno R, Takala J, Willatts S, de Mendonca A, Bruining H . The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996; 22(7):707-10. DOI: 10.1007/BF01709751. View

Ameloot K, Genbrugge C, Meex I, Jans F, Boer W, Vander Laenen M . An observational near-infrared spectroscopy study on cerebral autoregulation in post-cardiac arrest patients: time to drop 'one-size-fits-all' hemodynamic targets?. Resuscitation. 2015; 90:121-6. DOI: 10.1016/j.resuscitation.2015.03.001. View

Hekimian G, Baugnon T, Thuong M, Monchi M, Dabbane H, Jaby D . Cortisol levels and adrenal reserve after successful cardiac arrest resuscitation. Shock. 2004; 22(2):116-9. DOI: 10.1097/01.shk.0000132489.79498.c7. View

10.

Annane D, Bellissant E, Sebille V, Lesieur O, Mathieu B, Raphael J . Impaired pressor sensitivity to noradrenaline in septic shock patients with and without impaired adrenal function reserve. Br J Clin Pharmacol. 1998; 46(6):589-97. PMC: 1873798. DOI: 10.1046/j.1365-2125.1998.00833.x. View

11.

Bro-Jeppesen J, Kjaergaard J, Stammet P, Wise M, Hovdenes J, Aneman A . Predictive value of interleukin-6 in post-cardiac arrest patients treated with targeted temperature management at 33 °C or 36 °C. Resuscitation. 2015; 98:1-8. DOI: 10.1016/j.resuscitation.2015.10.009. View

12.

Annane D . Glucocorticoids in the treatment of severe sepsis and septic shock. Curr Opin Crit Care. 2005; 11(5):449-53. DOI: 10.1097/01.ccx.0000176691.95562.43. View

13.

Fergusson D, Aaron S, Guyatt G, Hebert P . Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis. BMJ. 2002; 325(7365):652-4. PMC: 1124168. DOI: 10.1136/bmj.325.7365.652. View

14.

Cooper M, Stewart P . Corticosteroid insufficiency in acutely ill patients. N Engl J Med. 2003; 348(8):727-34. DOI: 10.1056/NEJMra020529. View

15.

Kroll S, El-Gindi J, Thanabalasundaram G, Panpumthong P, Schrot S, Hartmann C . Control of the blood-brain barrier by glucocorticoids and the cells of the neurovascular unit. Ann N Y Acad Sci. 2009; 1165:228-39. DOI: 10.1111/j.1749-6632.2009.04040.x. View

16.

Trzeciak S, Jones A, Kilgannon J, Milcarek B, Hunter K, Shapiro N . Significance of arterial hypotension after resuscitation from cardiac arrest. Crit Care Med. 2009; 37(11):2895-903. DOI: 10.1097/ccm.0b013e3181b01d8c. View

17.

Ullian M . The role of corticosteriods in the regulation of vascular tone. Cardiovasc Res. 1999; 41(1):55-64. DOI: 10.1016/s0008-6363(98)00230-2. View

18.

Tatro J . Endogenous antipyretics. Clin Infect Dis. 2000; 31 Suppl 5:S190-201. DOI: 10.1086/317519. View

19.

Venkatesh B, Finfer S, Cohen J, Rajbhandari D, Arabi Y, Bellomo R . Adjunctive Glucocorticoid Therapy in Patients with Septic Shock. N Engl J Med. 2018; 378(9):797-808. DOI: 10.1056/NEJMoa1705835. View

20.

Tuure L, Hamalainen M, Nummenmaa E, Moilanen T, Moilanen E . Downregulation of microsomal prostaglandin E synthase-1 (mPGES-1) expression in chondrocytes is regulated by MAP kinase phosphatase-1 (MKP-1). Int Immunopharmacol. 2019; 71:139-143. DOI: 10.1016/j.intimp.2019.03.014. View